Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of quinazoline compounds and avastin in preparation of disease-prevention combined drugs

A quinazoline and compound technology, which can be used in drug combinations, neurological diseases, anti-tumor drugs, etc., can solve problems such as toxic and side effects, achieve good efficacy, prolong the time required for drug resistance, and prolong progression-free survival. Effect

Active Publication Date: 2019-10-22
WEISHANG (SHANGHAI) BIO PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As known to those skilled in the art, a single drug with dose-dependent efficacy can advantageously inhibit the growth of cancer cells at high doses, but may produce greater toxic side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of quinazoline compounds and avastin in preparation of disease-prevention combined drugs
  • Use of quinazoline compounds and avastin in preparation of disease-prevention combined drugs
  • Use of quinazoline compounds and avastin in preparation of disease-prevention combined drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Inhibitory effect of Avastin-quinazoline derivatives (I) according to the present invention on xenograft tumor growth in non-small cell lung cancer PC-9 mice

[0022] Non-small cell lung cancer PC-9 cancer cells (5x 10 6 ), in 0.1ml of RPMI-1640andMatrigel (BD, cat.NO.356234) (1:1ratio) cell suspension, inoculated subcutaneously in the right wing of mice. After 8 days, use a vernier caliper to measure the diameter of the mouse transplanted tumor, and wait until the tumor grows to 150-200mm 3 Animals were then randomly grouped. Using the method of measuring tumor diameter, dynamically observe the antitumor effect of the tested drug. Tumor diameter was measured once every 3 days, and the weight of the mouse was also weighed at the same time as each measurement. The grouping and administration methods are as follows:

[0023] The Avastin group was injected intraperitoneally, 5 mg / kg, twice a week. The quinazoline derivative (I) group of the present invention was admin...

Embodiment 2

[0025] Drug efficacy of PC-9 tumor cell mouse subcutaneous animal model

[0026] like figure 1 As shown, in the drug efficacy experiment of PC-9 tumor cell mouse subcutaneous animal model, administration began on the eighth day after planting tumor cells, and the second group of quinazoline derivatives (I) single drug, 1 mg / kg, orally , twice a day and the third group of Avastin, single drug, intraperitoneal administration, twice a week compared with the first group of the control group (without drug group) all showed good inhibition of tumor growth, with statistically significant drug effects .

[0027]

[0028] The fourth group (quinazoline derivative (I) and Avastin composition) of the pharmaceutical composition of the present invention unexpectedly shows a synergistic effect, and improves the efficacy of a single drug compared with the second group and the third single drug group , and there was a statistically significant difference in efficacy. Compared with the bl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of quinazoline compounds and avastin in preparation of disease-prevention combined drugs. The quinazoline compounds include at least one of the quinazoline derivatives represented by the formula I and salts, prodrugs, prodrug salts, solvates, hydrates and polymorphic substances thereof. Compared with the prior art, the quinazoline compounds and avastin have the following beneficial effects: 1, the composition of the quinazoline derivatives (I) and the pharmaceutical salts thereof and avastin has unexpected synergistic effect, and has better curative effect than single drug, such as cancer, cancer brain metastasis, cancer meningeal metastasis, brain cancer, nerve center disease and the like; and 2, the composition of the quinazoline derivatives (I) and the pharmaceutical salts thereof and avastin can prolong the time required for cancer cells to generate drug resistance, and prolongs the disease progression-free survival period.

Description

technical field [0001] The invention relates to the use of quinazoline compounds and Avastin in the preparation of combined drugs for preventing diseases, and belongs to the technical field of biomedicine. Background technique [0002] Quinazoline derivatives with the blood-brain barrier, molecular formula C 23 h 21 f 3 N 4 o 2 , chemical name (R)-6-[(3,3-difluoro-1-methylpiperidin-4-yl)oxy]-nitrogen-(3-ethynyl-2-fluorophenyl)-7- Methoxyquinazolin-4-amine (I), which is a molecularly targeted antineoplastic drug, is a highly selective epidermal growth factor receptor EGFR tyrosine kinase inhibitor and can be used for the treatment of non-small cell lung cancer Brain metastasis, meningeal metastasis, head and neck squamous cell carcinoma, squamous cell carcinoma, brainstem tumor, primary brain cancer, glioma or other cancers, etc. Chinese patent 201610982608.6 describes the above-mentioned quinazoline derivatives (I) (molecular formula C 23 h 21 f 3 N 4 o 2 ) prepar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K31/517A61P35/00A61P35/04A61P25/00
CPCA61K39/3955A61K31/517A61P35/00A61P35/04A61P25/00A61K2300/00
Inventor 钟卫张金强
Owner WEISHANG (SHANGHAI) BIO PHARMA CO LTD
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com